Enhancing immunotherapy for CLL patients with ibrutinib
MRD studies in ALL and AML
Novel lymphoma targets and agents
Andrew Zelenetz et al.
IDH inhibition in AML therapy
Comparing ibrutinib efficacy and toxicity levels by age for patients with CLL/SLL